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When the tumour suppressor p53 is activated by DNA damage, it stimulates the transcription of its target genes, which then induce
cell cycle arrest or apoptosis. Here, we examined the role p53 plays in the antitumour effect of combination treatment with pegylated
interferon (PEG-IFN)-a and 5-fluorouracil (5-FU), which has been shown to effectively treat advanced hepatocellular carcinoma
(HCC). Nude mice were injected subcutaneously with cultured HepG2 cells, in which p53 is functional. They were treated a week
later with PEG-IFN and/or 5-FU for 7 weeks, after which we measured and examined their tumours. Combination groups showed
significantly lower tumour volumes and higher tumour cell apoptosis than the other groups. Combination treatment and PEG-IFN
monotherapy also significantly elevated the p53 protein and mRNA levels in the tumour but only combination treatment increased
the degree of p53 phosphorylation at serine46 and induced p53-regulated apoptosis-inducing protein 1 (p53AIP1) expression. The
antitumour effects of combination treatment is due in part to the elevation by PEG-IFN of p53 protein and mRNA expression and in
part to the DNA damage that is generated by 5-FU, which induces p53 serine46 phosphorylation, which in turn upregulates p53AIP1
expression.
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Hepatocellular carcinoma (HCC) has a poor prognosis worldwide.
Although the treatment of choice is generally resection, patients
with HCC that is unresectable due to advanced disease or hepatic
dysfunction are treated by radiofrequency ablation (RFA) and
arterial embolisation. However, none of these local treatments are
suitable for patients whose HCC has invaded the portal vein.
Recent studies have suggested that these patients may be
effectively treated by combination therapy involving subcutaneous
(s.c.) administration of interferon (IFN)-a and intrahepatic
administration of 5-fluorouracil (5-FU) (Sakon et al, 2002; Obi
et al, 2006). A Phase II trial has also revealed that continuous 5-FU
infusion combined with thrice-weekly treatment with IFN-a
effectively treats HCC, perhaps because the drugs together play a
neoadjuvant role (Patt et al, 2003). Comprehensive genetic
analyses with PCR arrays have revealed that this method may be
useful for predicting whether combination chemotherapy with
IFN-a and 5-FU can successfully treat HCC (Kurokawa et al, 2004).
However, despite these observations, the molecular mechanisms
behind the anti-HCC activity of IFN-a/5-FU combination therapy
remain poorly understood.
The IFN-a group of closely related cytokines are typically
produced early after infection with viruses and have antiviral and
immunoregulatory activities (Samuel, 2001; Takaoka et al, 2003).
They also have potent antitumour activities (Samuel, 2001;
Takaoka et al, 2003). While studies examining the IFN-a-mediated
signal transduction pathways have already identified a number of
IFN-a-induced genes, it remains unclear whether these genes
contribute to the antitumour activities of IFN-a. The IFN-a
cytokines appear to exert their antitumour activities both
indirectly by activating immune cells such as natural killer cells,
macrophages, and dendritic cells (Biron, 2001; Belardelli et al,
2002), and directly by inducing apoptosis (Clemens, 2003). With
regard to the latter activity, the consensus IFN-a, which is a non-
naturally occurring type I IFN with higher specific activity than the
natural type I IFNs, has been shown to suppress the growth of HCC
both in vitro and in vivo (Hisaka et al, 2004). Additional studies
have suggested that pegylated interferon (PEG-IFN)-a, where IFN-a
is joined by an amide linkage to a 40kDa branched polyethylene
glycol (PEG), may have even better antitumour effects in vivo. For
example, Bailon et al (2001) showed that PEG-IFN-a has more
potent antitumour activity on human kidney-derived cancer cells
in vivo than IFN-a. The pegylation of IFN appears to stably
maintain an effective concentration of IFN in the blood (Perry
et al, 2001).
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sThe tumour suppressor gene p53 is activated by the DNA
damage that is induced by X-rays, ultraviolet (UV) rays, or
anticancer drugs like 5-FU. Its protein then stimulates the
transcription of its target genes, which induce cell cycle arrest or
apoptosis. As a result, p53 is frequently inactivated by mutations in
tumour cells (Prives et al, 1999; Vogelstein et al, 2000; Vousden
et al, 2002). Upon its phosphorylation at serine46, p53 also
regulates the transcriptional activation of p53-regulated apoptosis-
inducing protein 1 (p53AIP1), which probably plays an important
role in mediating p53-dependent apoptosis (Oda et al, 2000).
Recently, the combination of 5-FU and IFN-a was found to
suppress HCC proliferation by elevating S-phase arrest and
apoptosis (Kojiro et al, 2006). Given the central role p53 plays in
the induction of cell cycle arrest and apoptosis, it is possible that
the IFN-a/5-FU combination therapy activates p53 in some way.
Supporting this is that IFN-a has been found to induce p53 gene
expression (Takaoka et al, 2003; Vilcek, 2003). To test whether p53
participates in the anti-HCC activity of IFN-a/5-FU combination
therapy, we here treated nude mice carrying HepG2 cell tumours
with 5-FU and/or IFN-a. HepG2 cells express functional p53. Our
observations suggest that PEG-IFN-a elevates p53 protein expres-
sion, and that this, in combination with the DNA damage elicited
by 5-FU, leads to enhanced HCC cell apoptosis in vivo.
MATERIALS AND METHODS
Cell lines and cell culture
The human HCC cell line HepG2 was obtained from the Health
Science Research Resources Bank (Sennan, Japan) and was grown
in Dullbecco’s modified Eagle’s medium (DMEM) (Sigma-Aldrich,
St Louis, MO, USA) supplemented with 10% foetal bovine serum
(FBS) (JRH Bioscience, St Lenexa, KS, USA) at 371C under 5% CO2/
95% air.
Animals
Male BALB/c nude mice, aged 4 weeks, were purchased from Clea
Japan, Inc. (Tokyo, Japan) and acclimated for a week.
Compounds and study design
5-FU and PEG-IFN-a 2a (PEGASYS
s) were supplied by Kyowa
Hakko Kogyo Co., Ltd (Tokyo, Japan) and Chugai Pharmaceutical
Co., Ltd. (Tokyo, Japan), respectively. The 5-week-old male BALB/
c nude mice were injected s.c. with cultured HepG2 cells (10
6 cells
per mouse). When the tumour was 5–10mm in diameter (7 days
later), the mice were randomly divided into five groups of five:
Group 1 (control group) received phosphate-buffered saline (PBS),
Group 2 (5-FU group) received 10mgkg
 1day
 1 5-FU, Group 3
(high-dose 5-FU) received 20mgkg
 1day
 1 5-FU, Group 4
(PEG-IFN) received 1.5mgkg
 1 PEG-IFN-a, while Group 5
(combination) received 10mgkg
 1 5-FU and 1.5mgkg
 1 PEG-
IFN-a. Note that Groups 2, 4, and 5 can be directly compared
because they received the same doses of the two compounds. 5-FU
was delivered intraperitoneally (i.p.) five times a week while PEG-
IFN-a was injected s.c. once a week. The animals were treated for 7
weeks. Tumour size was measured once a week in two directions
by using calipers, and tumour volume was estimated by using the
equation: length (the width)
2 (each week)/the length (the
width)
2 (0 week). At the end of the experiments, the mice were
killed under ether anaesthesia and their tumours were examined as
detailed below. All animal procedures were performed according
to approved protocols and in accordance with the recommenda-
tions for the proper care and use of laboratory animals. The
Medical Ethics Committee of Kinki University School of Medicine
approved the study (October 2004).
Histopathological examination and detection of apoptosis
The tumours were resected and fixed in formalin. The tumour
sections with the largest diameter were prepared as paraffin
sections for haematoxylin and eosin (HE) staining. To detect
apoptotic cells, the In situ Cell Death Detection Kit, TMR red
(Roche Diagnostics GmbH, Mannheim, Germany) was used
(TUNEL technology). The numbers of apoptotic cells in ten 1.35-
mm
2 areas of each HE-stained specimen where apoptotic cells were
present at a relatively uniform density were determined under a
fluorescence microscope. These counts were averaged to obtain the
number of apoptotic cells per specimen.
Immunoprecipitation and immunoblot analysis
Cell lysis, immunoprecipitation and immunoblotting were per-
formed as described (Lehtonen et al, 2004). The p53 proteins were
immunoprecipitated with an anti-p53 antibody (Ab-1; Oncogene
Research Products, Cambridge, MA, USA) and immunoblotted by
using rabbit IgG TrueBlot (eBioscience, San Diego, CA, USA) and
anti-p53 or anti-p53-phospho-serine46 (Cell Signaling Technology,
Danvers, MA, USA) antibodies. As a control, the supernatants
obtained after p53 immunoprecipitation were directly subjected to
immunoblotting with anti-b-actin antibody (Clone AC-74; Sigma-
Aldrich, St Louis, MO, USA).
RNA extraction and real-time RT–PCR
Total RNA was isolated from the HepG2 tumours by employing an
RNeasy Mini kit (Qiagen, Hilden, Germany). Total RNA (200mg)
was converted into cDNA in accordance with the manufacturer’s
instructions (ReverTra Ace, TOYOBO, Osaka, Japan). The reaction
was performed at 301C for 10min, 421C for 20min, and 991C for
5min. Quantitative PCR was performed in 96-well plates by using
the TaqMan probe assay (ABI Prism 7700; Perkin-Elmer, Waltham,
MA, USA) (Eickhoff et al, 2000; Gautschi et al, 2001). For this,
pairs of primers and TaqMan probes were designed by a Perkin-
Elmer to amplify specific small fragments from p53 (Assay ID;
Hs00153349) and p53AIP1 (Assay ID; Hs00223141). In addition, a
pair of primers and a TaqMan probe designed for human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Perkin-
Elmer) were used as an internal standard of mRNA integrity
within the experiment. The final reaction mixture contained
1 TaqMan Universal PCR Master Mix (AmpliTaq Gold, AmpErase
UNG, dNTP and dUTG, and optimised buffer) (Perkin-Elmer),
1 p53 Mix or 1 p53AIP1 Mix, and 1 Control (GAPDH) Mix.
The cycling conditions comprised an initial phase of 501C for 2
and 10min at 951C that was followed by 50 cycles of 15s at 951C
and 1min at 601C.
Statistical analyses
The data are expressed as means±standard deviation. The
statistical significance of differences between two groups was
determined by Student’s t-test. A probability value of 0.05 or less
was considered to be significant.
RESULTS
HepG2 tumour cell growth in nude mice
The Group 3 mice, which received high-dose 5-FU
(20mgkg
 1day
 1), were excluded from the following analyses
because they all died within 3 weeks of treatment.
High-dose 5-FU also induced marked weight loss (date not
shown). In contrast, treatment with 10mgkg
 1day
 1 5-FU and/or
1.5mgkg
 1week
 1 PEG-IFN-a did not affect the body weight of
the mice (data not shown). The volumes of the tumours over the
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s7 weeks of treatment are shown in Figure 1A. When we compared
the tumour volumes at the end of the experiment, Group 2 (5-FU),
Group 4 (PEG-IFN), and Group 5 (combination) showed
significantly lower tumour volumes than the control (Group 1).
Furthermore, the tumour volumes of the combination group were
significantly lower than those of the 5-FU and PEG-IFN mono-
therapy groups (Po0.05, Figure 1B).
Histopathological examination and detection of apoptosis
Photomicrographs of the HE-stained tumour sections taken from
the control and combination-treated animals at the end of the
experiment did not reveal any marked differences between the
two groups, although the control group tumours did show some
necrosis, unlike the combination group tumours. This is because
the control group tumours were significantly larger. We then
examined the 7-week tumour sections for apoptosis by TUNEL
analysis. Representative TUNEL-stained tumour sections are
shown in Figure 2A. The tumours from the combination-treated
animals had significantly more apoptotic cells (9.0±1.4/1.35mm
2
area) than the tumours from all the other groups (Po0.05,
Figure 2B). The tumours from the animals treated only with 5-FU
(6.2±0.7) or PEG-IFN (4.6±0.8) also had significantly more
apoptotic cells than the control tumours (2.4±1.1) (Po0.05).
Immunoprecipitation, immunoblot analysis and real-time
RT–PCR
We next determined the p53 protein and mRNA levels in the
7-week tumours by Western blot analysis and real-time RT–PCR,
respectively (Figures 3 and 4). The degree of p53 phosphorylation
on serine46 protein and the p53AIP1 mRNA levels were also
measured by Western blot analysis and real-time RT–PCR,
respectively (Figures 3 and 4).
The extracted tumour proteins (700mg) were immunoprecipi-
tated by using an anti-p53 antibody and then immunoblotted with
anti-p53 or anti-p53-phospho-serine46 antibodies. The combina-
tion- and PEG-IFN-treated tumours had higher p53 levels than the
control and 5-FU-treated tumours. The degree of p53 phosphory-
lation on serine46 was also significantly higher in the combination



















































Figure 2 Incidence of apoptotic cells in TUNEL-stained 7-week tumour
sections. The In situ Cell Death Detection Kit, TMR red was used to detect
apoptotic cells in tumour sections. (A) Representative TUNEL-stained
tumour sections from the G1 (control), G2 (5-FU), G4 (PEG-INF), and G5
(combination) groups. ( 100). (B) Average apoptotic cell numbers in
TUNEL-stained tumour sections. Ten 1.35mm
2 areas in the HE-stained
specimen that showed apoptotic cells in a relatively uniform density were
selected for apoptotic cell counting. The 10 counts were then averaged to
yield the data for the individual mice. The data shown are the average
counts of the five mice in each group. The G5 tumours had significantly
more apoptotic cells than all other groups, while the G2 and G4 tumours
had significantly more apoptotic cells than the G1 tumours. The error bar
represents s.d. *Statistically significant difference compared with G1, G2,
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Figure 1 Tumour volumes of 5-FU- and/or PEG-IFN-a-treated nude
mice bearing s.c. HepG2 cell tumours. Mice bearing 5–10mm diameter s.c.
HepG2 cell tumours were treated with PBS (G1, control group), 5-FU at
10 (G2, 5-FU) or 20 (G3, high-dose 5-FU)mgkg
 1day
 1 only, PEG-IFN-a
at 1.5 (G4, PEG-IFN), or with both at 10mgkg
 1day
 1 5-FU and
1.5mgkg
 1week
 1 PEG-IFN-a (G5, combination). (A) Change in tumour
volume over time. G1 (&), G2 ( ), G4 (D), and G5 (J). The G3 group is
not shown because these mice did not survive beyond 3 weeks of
treatment. (B) Tumour volumes at the end of the experiment after 7
weeks of treatment. *Statistically significant difference compared with G1,
G2, and G4 (Po0.05). **Statistically significant difference compared with
G1 (Po0.05).
PEG-IFN-a and 5-FU inhibit HepG2 tumour growth via p53
S Hagiwara et al
1534

























sequivalent serine46 phosphorylation (Figure 3). When we exam-
ined the phosphorylation of p53 on serine15 and serine20, none of
the groups showed any differences (data not shown).
Figure 4A shows the expression of p53 mRNA normalised to that
of GAPDH. The expression of p53 mRNA in the combination- and
PEG-IFN-treated tumours was significantly increased about 2.7-
fold and about 2.6-fold in comparison to that in the control
tumours, respectively. In addition, the level of p53AIP1 mRNA in
the combination-treated tumours was significantly increased about
2.8-fold when compared with that in the control tumours
(Figure 4B).
DISCUSSION
Interferon-a treatment on its own has been known to have an
antitumour effect (Biron, 2001; Belardelli et al, 2002; Clemens,
2003; Hisaka et al, 2004). Indeed, a previous study has shown that
IFN-a directly prevents and delays hepatocarcinogenesis by
suppressing pre-neoplastic cell proliferation although this study
also found that this effect may depend in part on the induction
of p21 via a p53-independent pathway (Nakaji et al, 2004). In
addition, long-term, low-dose, intermittent IFN-a therapy was
shown to successfully delay the clinical recurrence of HCC after
radical RFA therapy (Sakaguchi et al, 2005). These observations
are consistent with those of the present experiment, which revealed
that treatment with PEG-IFN on its own quite efficiently
suppressed tumour growth.
Their combination of IFN-a and 5-FU has been shown
previously to be highly effective clinically (Sakon et al, 2002;
Patt et al, 2003; Obi et al, 2006). This is supported by our own
observation that combination therapy with IFN-a and 5-FU
induced significantly more apoptosis and tumour growth inhibi-
tion than monotherapy. This suggests that when IFN-a and 5-FU
are combined, they act additively or synergistically to inhibit HCC.
The mechanism behind this effect has been explored by several
studies. One study reported that IFN-a activates thymidine
phosphorylase (TP), which then metabolises 5-FU at higher rates,
thereby increasing the intracellular levels of the active metabolite
5-fluoro-20-deoxyuridine 5-monophosphate (FdUMP) (Schwartz
et al, 1992). Interferon-a may also enhance the anti-HCC effect
of capecitabine in nude mice by a similar mechanism (Xiao et al,
2004). Another study found that IFN-a inhibits thymidylate
synthetases (TS), thereby enhancing 5-FU activity (Dou et al,
2005). In addition, the combination therapy has been shown to
impair HCC growth by delaying the cell cycle and inducing
apoptosis, since IFN-a/5-FU-treated human HCC cell lines show
cell accumulation in the G0/G1 phase and increased expression of
the cell cycle-related protein p27
Kip1 (Eguchi et al, 2000). Thus, it is
possible that IFN-a and 5-FU may together induce cell cycle arrest
and apoptosis. Various mechanisms may be involved in this effect.
First, the known proapoptotic effect of 5-FU that arises from the
DNA damage it causes may be augmented in an additive manner
by IFN-a, which may induce apoptosis by triggering the IFN-a/b
receptor, which can then activate the signal transducer and
activator of transcription (STAT)1 protein; STAT1 in turn
regulates the expression of the Bcl-2 family of apoptosis-related
proteins. Supporting the possibility that this mechanism is
involved in the superior efficacy of the combination therapy, it
has been noted that the growth-inhibitory effect of combination
therapy is particularly marked in cell lines that express high levels
of IFN-a/b receptors (Kondo et al, 2000, 2005; Ota et al, 2005).
IFN-a and 5-FU may also act synergistically to induce HCC
apoptosis due to the ability of both molecules to modulate the
tumour necrosis factor-related apoptosis-induced ligand (TRAIL)/
TRAIL receptor-mediated cytotoxic pathway. Here, IFN-a elevates
TRAIL expression by activating antitumour effectors while 5-FU
enhances TRAIL-receptor expression by HCC cells (Yamamoto
et al, 2004).
Our study here also suggests strongly that IFN-a/5-FU
combination treatment induces apoptosis and suppresses HCC
proliferation by activating mechanisms that involve p53. P53 plays
an essential role in the induction of cell cycle arrest and apoptosis.
Blot: anti-p53
IP: anti-p53
G5 G2 G4 G1
Blot: anti-p53
        -phopho-serine46
Blot: anti--actin
Figure 3 p53 levels and degree of p53 phosphorylation on serine46
in 7-week tumours. The extracted proteins (700mg) were subjected to
immunoprecipitation with anti-p53 and immunoblot (Blot) analysis with
anti-p53 or anti-p53-phospo-serine46 antibodies. As a control, the
supernatants after p53 immunoprecipitation were directly subjected to
immunoblotting using an anti-b-actin antibody. G1, control group; G2, 5-FU
group; G4, PEG-IFN group; G5, combination group. The G4 and G5
tumours had higher p53 levels than the G1 and G2 tumours while the




















































































































Figure 4 Quantitative RT–PCR analysis of p53 (A) and p53AIP1 (B)
mRNA expression in 7-week tumours. Total RNA (200mg) isolated from
the HepG2 tumours was subjected to TaqMan real-time PCR. The data
were analysed on the basis of the Ct values of each sample and normalised
relative to the GAPDH mRNA levels. The G4 and G5 groups showed
increased p53 mRNA expression in their tumours compared to the G1 and
G2 groups. The G5 tumours showed significantly increased p53AIP1
mRNA levels when compared with the other tumours. The error bar
represents s.d. *Statistically significant difference compared with G1 and G2
(Po0.05). **Statistically significant difference compared with G1, G2, and
G4 (Po0.05).
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sThat p53 may be involved in the superior efficacy of the
combination treatment has been suggested previously by a study
showing that the antitumour effects of 5-FU and cisplatin correlate
with p53 activity (Longley et al, 2003; Mujoo et al, 2003).
Moreover, the IFN-stimulated gene factor3 (ISGF3) formed by
IFN-a has been shown to induce p53 gene expression by binding to
at least two IFN-stimulated response element (ISRE) sites in the
p53 gene (Takaoka et al, 2003; Vilcek, 2003). We found that while
the HepG2 tumours of PEG-IFN- and combination-treated animals
showed significantly elevated p53 protein and mRNA levels, only
the combination-treated tumours showed increased p53 phosphory-
lation at serine46 and elevated p53AIP1 mRNA levels. P53AIP1
occurs only upon severe DNA damage, is activated by p53 after the
latter is phosphorylated at serine 46, and appears to control the
apoptosis-inducing function of p53 (Oda et al, 2000). These
observations together suggest that upon combination therapy,
PEG-IFN increases p53 protein levels while 5-FU induces tumour
cell DNA damage that activates the p53 molecules generated by
PEG-IFN. This may be responsible, at least in part, for the superior
apoptosis-inducing and tumour-inhibiting effects of this treatment
regimen.
Notably, in the present experiment, none of the treatments
altered the degree of p53 protein phosphorylation at serine15 or
serine20 (data not shown). After DNA damage, p53 phosphoryla-
tion first occurs at serine15 or 20, which stabilises and activates
p53; p53 then binds to the promoters of G1 arrest-related genes
such as p21
waf1 and DNA repair-related genes such as p53R2 to
induce their expression. If the DNA damage is severe enough,
p53 then becomes phosphorylated at serine46 and induces apoptosis.
Since only the combination group showed significantly increased
serine46 phosphorylation, this suggests that the 5-FU component
of this treatment regimen caused such severe DNA damage that the
cells could not recover by inducing G1 arrest and DNA repair, thus
resulting in serine46 phosphorylation and HCC apoptosis.
In this study, to determine the role of p53 plays in PEG-IFN/
5-FU combination treatment efficacy, we selected the HepG2 cell
line, as its p53 molecule is functional and does not bear mutations.
Clearly, cell in which p53 is mutated and dysfunctional or even
lacking may be significantly less susceptible to PEG-IFN/5-FU
combination therapy than HepG2. Indeed, when Takaoka et al
(2003) compared the effect of combination therapy on the HLE cell
line, in which p53 is dysfunctional, and HepG2 in vitro, they found
that the therapy killed HepG2 but not HLE. Thus, future studies
should examine whether p53-mutated or -negative tumour cells
can be susceptible to combination therapy in vivo.
In conclusion, recent studies have reported that IFN/5-FU
combination therapy can effectively treat patients with advanced
HCC (Sakon et al, 2002; Obi et al, 2006). Our present study reveals
PEG-IFN/5-FU combination therapy operates at least in part by
enhancing the proapoptotic function of p53.
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